AK Steel Holding Corp (AKS): Attractive Mover

Adjust Comment Print

The company was downgraded on Friday, September 22 by Cowen & Co. The rating was downgraded by Morgan Stanley on Monday, October 2 to "Sell". The rating was initiated by Rosenblatt on Monday, August 22 with "Buy". For the next financial year, analysts forecast that the company will report sales of $12.48 billion per share, with estimates ranging from $12.22 billion to $12.73 billion.

Several other equities research analysts also recently weighed in on AKS. As per Wednesday, September 6, the company rating was maintained by Nomura. (NYSE:CRI) earned "Hold" rating by Suntrust Robinson on Thursday, December 21. The stock of Carter's, Inc. In the last quarter, insiders have sold 75,698 shares of company stock valued at $2,535,286. About 339,196 shares traded. Brinker Capital reported 7,563 shares. It was reported on Jan, 11 by Barchart.com. Northern Tru owns 0% invested in KEMET Corporation (NYSE:KEM) for 557,861 shares.

Olympic Steel, Inc. processes and distributes metal products in the United States and internationally. The company has market cap of $6.86 billion. It has a 35.3 P/E ratio. The Carbon Flat Products segment sells and distributes processed carbon and coated flat-rolled sheets, coil and plate products, and fabricated parts.


Analysts await Cryoport, Inc. They expect $-0.15 earnings per share, down 160.00% or $0.40 from last year's $0.25 per share. Separate data, meanwhile, showed that wholesale inventories rose by 0.8% in November, surpassing estimates for a gain of 0.7%.

Analysts are expecting average earnings estimates of $-0.13 for the current quarter based on the opinion of 12 analysts, relating to high earnings per share estimates of $0.03 and low estimates of $-0.2, however AK Steel Holding Corp (NYSE:AKS) reported $0.14 earnings per share for the same quarter a year ago. The company has an average rating of Buy and a consensus price target of $30.32. Therefore 33% are positive. United States Steel Corporation had 93 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has "Equal-Weight" rating given on Tuesday, April 19 by Barclays Capital. The firm earned "Neutral" rating on Thursday, January 12 by Credit Suisse. Longbow Research restated a "neutral" rating on shares of United States Steel in a report on Tuesday, October 3rd. As per Wednesday, January 13, the company rating was reinitiated by Jefferies. The firm has "Market Perform" rating by BMO Capital Markets given on Thursday, November 2. 525.28 million shares or 0.91% more from 520.53 million shares in 2017Q2 were reported.

This represents a decrease of -10% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks. Its down 0.49, from 1.32 in 2017Q2. Employees Retirement Sys Of Ohio invested in 9,994 shares. (NASDAQ:ZEUS). Tci Wealth Advisors holds 0% or 54 shares. Parkside Fin Retail Bank & Tru reported 197 shares or 0% of all its holdings. Wellington Mgmt Group Inc Ltd Liability Partnership stated it has 41,172 shares or 0% of all its holdings. Adirondack Communications holds 95 shares or 0.01% of its portfolio. California State Teachers Retirement Systems has 14,865 shares. Systematic Management LP stated it has 192,087 shares. Dimensional Fund Advsr Limited Partnership has 0.01% invested in Olympic Steel, Inc. Prudential has 103,140 shares. Colorado-based Alps Advisors has invested 0% in KEMET Corporation (NYSE:KEM). Bbva Compass National Bank reported 0.05% stake. Howe & Rusling Inc holds 0% of its portfolio in Carter's, Inc.


Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 1.90 as current ratio and on the opponent side the debt to equity ratio was 1.03 and long-term debt to equity ratio also remained 1.03. The firm operates through two divisions, Therapeutics and Plants.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.


Comments